Romiplostim: 9 agencies, 2009–2025
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 15.8 years separate the first record, 13 Jul 2009 at ZIN (Netherlands), from the most recent, 15 May 2025 at CONITEC (Brazil).
CONITEC (Brazil) changed its position: not recommended on 12 Dec 2018, recommended by 15 May 2025, after a resubmission.
No assessment is on file from PHARMAC (New Zealand), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
The file is active: 3 of 19 records date from 2023 or later.
5 distinct indication wordings are recorded for romiplostim by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 19 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
ZIN (Netherlands) was first to assess romiplostim, on 13 Jul 2009; PBAC (Australia) did not open a file until 2022 — an unusually long tail of 13 years between the earliest and latest system to look at it.
The record arrives in waves: 6 separate years each carry two or more decisions, spread across 11 years in total.
Restriction is doing real work here: 6 of 18 decisive outcomes narrowed romiplostim to a subgroup rather than accepting or refusing it outright, at AOTMIT (Poland), NICE (England) and SMC (Scotland) among others.
5 of the 9 agencies here assessed romiplostim more than once, CONITEC (Brazil) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
9 of the 18 agencies in this archive hold a record for romiplostim.
The full ledger for romiplostim reads 11 recommended, 6 restricted, 1 not recommended and 1 other.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CONITEC (Brazil) | 15 May 2025 | Tratamento da PTI refratária, crônica ou dependente de corticosteroide em crianças e adolescentes. | incorporated into SUS | source |
| PBAC (Australia) | 2022 | Thrombopoietin-receptor agonists (TPO-RAs) for primary immune thrombocytopenia (ITP) | Recommended | source |
| AOTMIT (Poland) | 15 Jun 2022 | programu lekowego B.97. „Leczenie dorosłych chorych na pierwotną małopłytkowość immunologiczną (ICD-10: D69.3) | recommended conditionally | source |
| AWMSG (Wales) | 5 Mar 2019 | Treatment of chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients aged 1 year to < 18 years who are refra… | recommended (limited) | source |
| HAS (France) | 31 Mar 2010 | Listing (Transparency Committee) | ASMR V | source |
14 further decisions for romiplostim, across 7 agencies, are not shown here. They link to 9 further source documents.
Related molecules
- emicizumab — same ATC class B02B — Antihemorrhagics
- eltrombopag — same ATC class B02B — Antihemorrhagics
- avatrombopag — same ATC class B02B — Antihemorrhagics
- concizumab — same ATC class B02B — Antihemorrhagics
- marstacimab — same ATC class B02B — Antihemorrhagics
- etranacogene dezaparvovec — same ATC class B02B — Antihemorrhagics
Coverage: 19 decisions for romiplostim from 9 agencies, 2009 to 2025. Data to 7 Sep 2026. ATC class B02B — Antihemorrhagics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.